-
Mashup Score: 4The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation - 2 month(s) ago
The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic stem cell transplantation (HSCT) for individuals with myelodysplastic syndromes (MDS) based on requests from ASH, ASTCT, NMDP, and CIBMTR.
Source: www.newswire.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Close - 2 month(s) ago
Use this page to view details for the decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndromes (MDS) (CAG-00415R).
Source: www.cms.govCategories: General Medicine News, Onc News and JournalsTweet-
CMS has reconsidered national coverage determinations for #alloHSCT for Myelodysplastic Syndromes. Read their final decisions, which allows physicians to make the best donor choice for their patients: https://t.co/JPOcc5RnPT @CMSGov https://t.co/6FoDQDfW9d
-
-
Mashup Score: 2Comparison of Seq, MAC, and RIC for patients with higher risk MDS - 3 month(s) ago
Potter V, Gras L, Koster L, et al. Sequential vs Myeloblative vs Reduced Intensity Conditioning for Patients With Myelodysplastic Syndromes With an Excess of Blasts at Time of Allogeneic…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
An analysis found outcomes after #alloHSCT in patients with higher-risk MDS are dictated primarily by baseline disease risk & individual characteristics, with choice of conditioning protocol having little impact. Read more on Nucleus: https://t.co/Bll46ppC0z https://t.co/2f7Kxw6Gvs
-
-
Mashup Score: 0Venetoclax Plus Conditioning Regimen for Patients With AML and FLT3-ITD-Mutated Undergoing AlloHSCT - 1 year(s) ago
Venetoclax plus a conditioning regimen yielded high overall survival among patients with AML undergoing allogeneic hematopoietic stem cell transplantation, and the FLT3-ITD gene mutation was revealed to be present in 51.6% of patients.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Venetoclax plus a conditioning regimen yielded high overall survival and low relapse rates among patients undergoing #alloHSCT for high-risk #AML. Read more about Dr Cao's research here: https://t.co/hMRRryaFsi https://t.co/UsacOwrwBV
-
-
Mashup Score: 0PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASTCTChat Q2: Should post-transplant cyclophosphamide #GVHD prophylaxis be the preferred regimen for 10/10 MUD selected for #alloHSCT in light of this study and the BMT CTN 1703 PROGRESS III results? https://t.co/HhXBCdk18q https://t.co/O5xOYbrusB
-
-
Mashup Score: 0
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant. https://t.co/4yFNbbdFgo #alloHSCT
-
-
Mashup Score: 0Please wait whilst we redirect you - 2 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hematologists1, Latest HeadlinesTweet-
Understanding pattern of #alloHSCT in #geriheme pts with #leusm Overall referral and transplant rates were low. #Performancestatus, age, disease and #comorbidity were common reasons for non-referral https://t.co/3p1pyMl4u0 @JGeriOnc https://t.co/3GyctF3cPv
-
-
Mashup Score: 0Patients Often Struggle With Cognitive Function After Allogeneic Hematopoietic Stem Cell Transplantation - 2 year(s) ago
Interviews with survivors of allogeneic hemotopoietic stem cell transplantation revealed their experiences with cognitive difficulties after treatment.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A study on the experiences of allogeneic hematopoietic stem cell transplantation recipients revealed the extent of cognitive impacts these survivors have faced. Study in @oncologynursing journal Oncology Nursing Forum. https://t.co/HbpD4vlGas #alloHSCT
-
-
Mashup Score: 0The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Stem Cell Transplant Daily! https://t.co/AO8mt1sYbA Thanks to @HematologyAdv #sragvhd #allohsct
-
ASTCT is encouraged by the @CMSGov decision to revise the National Coverage Determination of #alloHSCT, based on our recommendations. The revision offers full coverage to some MDS patients & is a step forward in providing life-saving treatment access. https://t.co/ozlYFBIbg3 https://t.co/bo4FiGaiA8